1524-P: Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes in a Spanish Population

Introduction: The prevalence of liver disease due to nonalcoholic fatty deposits (NAFLD) has doubled in the last 20 years in parallel to the increased prevalence of obesity and type 2 diabetes mellitus (T2DM). Insulin resistance is a central element in the pathogenesis of NAFLD and it is known that the prevalence of NAFLD is higher among patients with T2DM. Objective: To assess the prevalence of NAFLD in a sample of patients with T2DM and define the associated clinical characteristics. Methods: Observational, retrospective and multicenter study in routine clinical practice with SLGT2 inhibitor (dapaglifozin) and DPP-4 inhibitor (sitagliptin) in patients with T2DM in Spain (DAPA-RWE study). Protocol code:FIS-DAP-2016-01. Inclusion criteria were patients between 18-75 years old on treatment with sitagliptin or dapaglifozin for at least 6 months, minimum data set available. Data were analyzed with SSPPSS® version 24 (statistical significance level 0.05, mean data ± standard deviation). Results: Data from 1040 patients, belonging to 22 different centers, were analyzed. The average age of the patients is 59.6 ± 8.9, 50% were women and 45.7% were receiving treatment with insulin. In our sample, 8% of patients are diagnosed with NAFLD. Among patients with NAFLD the average BMI was 35 kg/m2 and the waist circumference was 111.83 cm compared to patients without NAFLD with an average BMI of 31 kg/m2 and a waist circumference of 102.36 mm. No statistically significant relationship was found between NAFLD and the development of ischemic heart attack (patients with NAFLD and Myocardial infarction were 11.9%) or neurovascular disease (patients with NAFLD and neurovascular disease were and 8.3%). Conclusions: In our sample, patients with NAFLD had higher BMI and waist circumference compared to patients without NAFLD. It has not been possible to demonstrate the relationship between NAFLD and cardiovascular or neurovascular disease, although the potency is limited by the low prevalence in our sample. Disclosure A.M. Sanchez Bao: None. V. Bellido: None. C. Tejera: None. D. Bellido: None.